Syndax names Metzger CEO as Morrison moves to President, Head of R&D

Syndax Pharmaceuticals Inc

Michael Metzger appointed CEO, effective immediately; previously President & COO.
Briggs Morrison becomes President, Head of R&D; remains on board.
Metzger base salary $640,000, target bonus 60% of base; Morrison base $637,500, bonus up to 50%.
Transition aligns roles with expertise; Metzger to focus on strategic vision and commercial prep.
Morrison to focus on advancing SNDX-5613 and axatilimab toward NDA filings in 2023.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Briggs W. Morrison, M.D.

President, Head of Research and Development

SNDX · Syndax Pharmaceuticals Inc

Effective: 2022-02-02
Successor: Michael A. Metzger
Filed: February 3, 2022, 6:59 PM ET

On February 2, 2022, Briggs W. Morrison, M.D., transitioned from his role as Chief Executive Officer and principal executive officer of Syndax Pharmaceuticals, Inc. (the “ Company ”) to President, Head of Research and Development of the Company.

Role change

Michael A. Metzger

Chief Executive Officer

SNDX · Syndax Pharmaceuticals Inc

Effective: 2022-02-02
Filed: February 3, 2022, 6:59 PM ET

On the same date, the Board appointed Michael A. Metzger, previously the Company’s President, Chief Operating Officer, and a member of the Board, to serve as the Company’s Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Briggs W. Morrison, M.D. changed role as President, Head of Research and Development at Syndax Pharmaceuticals Inc.

Action: transitioned
Role: President, Head of Research and Development

Exact text from the filing

On February 2, 2022, Briggs W. Morrison, M.D., transitioned from his role as Chief Executive Officer and principal executive officer of Syndax Pharmaceuticals, Inc. (the “ Company ”) to President, Head of Research and Development of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael A. Metzger was appointed as Chief Executive Officer at Syndax Pharmaceuticals Inc.

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On the same date, the Board appointed Michael A. Metzger, previously the Company’s President, Chief Operating Officer, and a member of the Board, to serve as the Company’s Chief Executive Officer.

View on SEC.gov

Syndax Pharmaceuticals Inc filing history →

Source: SEC EDGAR

accession 0001564590-22-003814

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.